The U.S. Radiopharmaceuticals market size is expected to be valued at US$ 3.6 billion in 2026 and projected to reach US$ 6.6 billion by 2033, growing at a CAGR of 9.0% between 2026 and 2033. Rising cancer incidence and growing adoption of precision nuclear medicine are the principal factors driving the U.S. radiopharmaceuticals market forward.

The National Cancer Institute estimates that over 2 million new cancer cases are diagnosed annually across the United States, intensifying demand for advanced diagnostic imaging and targeted radioligand therapies. Expanding PET and SPECT infrastructure, coupled with accelerated regulatory approvals from the U.S. Food and Drug Administration for novel theranostic agents, further reinforces sustained market momentum.

Drivers - Rising Cancer Incidence Across the United States Accelerating Demand for Nuclear Medicine

The escalating incidence of cancer across the United States stands as the foremost driver propelling the radiopharmaceuticals market. The National Cancer Institute projects that annual cancer diagnoses will continue rising over the coming decade, sustaining demand for early detection and targeted treatment tools nationwide.

Diagnostic radiopharmaceuticals such as Fluorine-18 (F-18) fluorodeoxyglucose remain indispensable for oncology staging via PET imaging, while therapeutic isotopes like Lutetium-177 (Lu-177) are increasingly prescribed for metastatic neuroendocrine tumors and prostate cancer. The Centers for Medicare & Medicaid Services continues to expand reimbursement coverage for radiopharmaceutical-based diagnostic and therapeutic procedures, reinforcing physician confidence and expanding adoption across hospitals and specialty cancer centers nationwide, thereby strengthening long-term market fundamentals.

Expanding Theranostics Pipeline and Accelerated FDA Approvals

A rapidly expanding theranostics pipeline, combining diagnostic imaging with matched therapeutic radioisotopes, is significantly strengthening market growth across the United States. The U.S. Food and Drug Administration has accelerated approval pathways for novel radioligand therapies, exemplified by the clearance of Pluvicto and Lutathera, both developed by Novartis AG, for prostate cancer and neuroendocrine tumors respectively. This regulatory momentum has encouraged substantial capital investment from companies such as Telix Pharmaceuticals Limited and Lantheus Holdings, Inc. into next-generation Gallium-68 (Ga-68) and Lutetium-177 (Lu-177) based agents. Growing collaboration between academic research institutes and radiopharmaceutical manufacturers across the country is also shortening development timelines, enabling faster commercialization of precision-targeted diagnostic and therapeutic combinations across oncology and neurology indications nationwide.

Restraints - Short Half-Life and Complex Domestic Supply Chain Logistics

The inherently short half-life of key radioisotopes such as Technetium-99m (Tc-99m), which decays within approximately six hours, poses significant logistical challenges for radiopharmaceutical manufacturers and distributors across the United States. This necessitates production facilities located near end-use sites and rapid, temperature-controlled distribution networks, substantially raising operational costs.

Periodic disruptions at aging research reactors, including maintenance shutdowns affecting domestic Molybdenum-99 supply, have historically triggered isotope shortages, delaying diagnostic procedures at hospitals and imaging centers nationwide. Such supply vulnerabilities discourage smaller healthcare providers from adopting radiopharmaceutical-based diagnostics, restraining broader market penetration in rural and underserved regions.

Stringent NRC and FDA Regulatory Compliance Requirements

Radiopharmaceuticals are subject to rigorous regulatory oversight governing production, handling, transportation, and disposal due to their radioactive nature. The U.S. Nuclear Regulatory Commission enforces strict licensing protocols for radioactive material handling, extending approval timelines for new manufacturing facilities and imaging centers nationwide. Compliance with radiation safety standards demands specialized infrastructure, trained personnel, and continuous monitoring, substantially increasing capital and operating expenditure. Smaller diagnostic imaging centers and specialty clinics across the country often lack resources to meet these stringent requirements, limiting their ability to offer radiopharmaceutical-based services and constraining overall market accessibility across price-sensitive regions.

Market Opportunities - Rising Adoption of Peptide Receptor Radionuclide Therapy (PRRT) Across U.S. Cancer Centers

Expanding clinical adoption of Peptide Receptor Radionuclide Therapy (PRRT) presents a substantial opportunity for radiopharmaceutical companies targeting neuroendocrine tumor treatment across the United States. Growing awareness among oncologists, combined with rising specialty cancer center investment, is driving demand for Lutetium-177 (Lu-177) based PRRT agents beyond established academic medical centers. Companies including Novartis AG and Telix Pharmaceuticals Limited are actively expanding domestic manufacturing capacity and distribution partnerships to serve growing demand nationwide. Furthermore, ongoing clinical trials evaluating PRRT combinations with immunotherapy, supported by the National Institutes of Health, are expected to broaden treatment indications beyond neuroendocrine tumors. As reimbursement frameworks continue to mature under evolving Centers for Medicare & Medicaid Services policy, radiopharmaceutical manufacturers with early regulatory filings and domestic production capabilities stand to capture significant first-mover advantage in these high-growth therapeutic segments.

Technological Advancements in Alpha-Emitting and Targeted Radioligand Therapies

The emergence of alpha-particle-emitting radioisotopes, such as Radium-223 (Ra-223) and investigational actinium-225 compounds, offers considerable growth potential due to their higher cytotoxic precision and reduced damage to surrounding healthy tissue compared to beta emitters. Eckert & Ziegler SE and SOFIE Biosciences are among companies investing in alpha-emitter production infrastructure across the United States to support next-generation targeted radionuclide therapy pipelines.

Academic and research institutes nationwide are simultaneously exploring novel chelator chemistries to improve isotope-antibody conjugation stability, enhancing therapeutic efficacy. As targeted radionuclide therapy transitions from bone-metastasis indications toward broader solid tumor applications, companies capable of securing consistent alpha-emitter supply chains and demonstrating favorable clinical outcomes through U.S. Food and Drug Administration trials are well-positioned to command premium pricing and expand their addressable patient population substantially through the forecast period.

Product Type Analysis

Diagnostic Radiopharmaceuticals dominate the U.S. market, commanding approximately 70% share in 2026, primarily attributable to their widespread integration into routine oncology, cardiology, and neurology imaging protocols nationwide. Technetium-99m (Tc-99m) based agents alone account for an estimated majority of nuclear medicine procedures performed annually across the United States, owing to their favorable imaging characteristics and cost-effectiveness for SPECT-based diagnostics.

Hospitals and diagnostic imaging centers continue to rely heavily on Fluorine-18 (F-18) fluorodeoxyglucose PET scans for cancer staging and treatment response monitoring. Meanwhile, Therapeutic Radiopharmaceuticals are registering the fastest growth going forward, propelled by expanding Lutetium-177 (Lu-177) and Radium-223 (Ra-223) based targeted therapies gaining U.S. Food and Drug Administration clearances for oncology indications nationwide.

Type of Radioisotope Analysis

Technetium-99m (Tc-99m) remains the leading radioisotope segment, accounting for an estimated 35% share of the U.S. radiopharmaceuticals market in 2026, owing to its dominant role in SPECT imaging across cardiology, oncology, and bone scintigraphy applications nationwide. Its short six-hour half-life and favorable gamma-ray energy make it ideal for same-day diagnostic procedures at hospitals and diagnostic imaging centers across the country. Domestic Molybdenum-99 supply reliability, supported by federal initiatives to strengthen non-highly enriched uranium-based production, continues to underpin consistent Tc-99m availability across major U.S. healthcare systems. Conversely, Lutetium-177 (Lu-177) is emerging as the fastest-growing radioisotope, driven by expanding therapeutic applications in neuroendocrine tumors and prostate cancer, supported by commercial success of agents such as Lutathera and Pluvicto from Novartis AG.

Northeast U.S. Radiopharmaceuticals Market Trends and Insights

The Northeast U.S. led the regional radiopharmaceuticals market, accounting for an estimated 34% share in 2026, supported by a high concentration of academic medical centers, comprehensive cancer institutes, and advanced nuclear medicine infrastructure. The region operates more than 700 PET-CT systems and hosts several leading radiopharmaceutical manufacturers and radiopharmacies, including Lantheus Holdings, Inc. Strong clinical research activity, favorable reimbursement policies, and widespread adoption of PET, SPECT, and theranostic procedures continue to drive demand. The presence of renowned institutions engaged in radiopharmaceutical innovation further reinforces the Northeast's leadership in both diagnostic and therapeutic nuclear medicine.

Southwest U.S. Radiopharmaceuticals Market Trends and Insights

The Southwest U.S. is projected to be the fastest-growing regional market through 2033, driven by rapid population growth, expanding oncology infrastructure, and increasing investments in nuclear medicine services. Texas alone operates more than 200 PET-CT systems, while major healthcare systems continue expanding radiopharmacy networks and theranostics capabilities. Growing cancer incidence, increasing adoption of Lutetium-177 (Lu-177) therapies, and rising investments in academic research collaborations are accelerating market growth. Continued expansion of diagnostic imaging facilities and favorable demographic trends are expected to strengthen demand for both diagnostic and therapeutic radiopharmaceuticals across the region.

West U.S. Radiopharmaceuticals Market Trends and Insights

The West U.S. maintained a significant share of the national radiopharmaceuticals market, supported by a strong biotechnology ecosystem and advanced healthcare infrastructure. California accounts for one of the largest concentrations of PET-CT installations in the country and serves as a hub for radiopharmaceutical research and commercialization. Increasing investments in theranostics, precision oncology, and molecular imaging continue to stimulate demand for innovative radiopharmaceutical products. Strong collaboration between biotechnology companies, academic research institutions, and healthcare providers supports ongoing clinical development and adoption of targeted radionuclide therapies, reinforcing the region's strategic importance within the U.S. market.

Midwest U.S. Radiopharmaceuticals Market Trends and Insights

The Midwest U.S. represented a stable contributor to the national radiopharmaceuticals market, supported by extensive hospital networks and established nuclear medicine programs. States such as Illinois, Ohio, and Minnesota continue expanding access to PET and SPECT imaging through investments in diagnostic infrastructure and cancer care services. The region benefits from strong academic medical centers conducting clinical research in molecular imaging and targeted radionuclide therapies. Growing demand for precision oncology, increasing utilization of radioligand therapies, and expanding collaborations between healthcare providers and radiopharmaceutical manufacturers continue to support steady market growth across the Midwest.

Southeast U.S. Radiopharmaceuticals Market Trends and Insights

The Southeast U.S. experienced steady growth in the radiopharmaceuticals market, supported by expanding healthcare infrastructure, increasing cancer prevalence, and rising investment in nuclear medicine services. Florida and Georgia continue adding PET-CT imaging systems and expanding access to advanced cancer treatment facilities. Growing adoption of molecular imaging for oncology, cardiology, and neurology, combined with increasing availability of targeted radionuclide therapies, continues to drive regional demand. Expansion of hospital networks, favorable demographic trends, and continued investment in radiopharmacy services are expected to strengthen the Southeast's role in supporting broader adoption of diagnostic and therapeutic radiopharmaceuticals.

The U.S. radiopharmaceuticals market remains moderately consolidated, with established players such as GE HealthCare, Curium Pharma, Novartis AG, and Siemens Healthineers AG (PETNET Solutions) maintaining strong positions through vertically integrated production and distribution networks. Companies are increasingly pursuing strategic collaborations, isotope supply agreements, and acquisitions to secure long-term Lutetium-177 (Lu-177) and Molybdenum-99 availability across domestic supply chains. Research and development investment is heavily focused on expanding theranostic pipelines and next-generation alpha-emitter therapies. Key differentiators among market leaders include proprietary radioisotope production capabilities, established U.S. regulatory track records, and extensive academic research partnerships. Emerging business models increasingly emphasize localized manufacturing near end-use hospitals to mitigate short half-life logistics challenges and strengthen domestic supply chain resilience.

Key Developments

• July 2026: Curium reported to be nearing an agreement to acquire radiopharmaceutical company Lantheus Holdings in a transaction valued at approximately US$7 billion. The proposed acquisition was expected to strengthen Curium's position in the global radiopharmaceutical market by expanding its portfolio of diagnostic imaging agents and therapeutic radiopharmaceuticals.
• June 2026: GE HealthCare announced initiatives to expand access to nuclear medicine by advancing innovations in artificial intelligence (AI), radiopharmaceuticals, and molecular imaging technologies. The company focused on enhancing diagnostic accuracy, streamlining clinical workflows, and improving patient access to precision imaging and targeted radionuclide therapies.